Syndax Pharmaceuticals (SNDX) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Syndax Pharmaceuticals (NASDAQ: SNDX) in the last few weeks:

• 11/4/2025 – Syndax Pharmaceuticals had its price target raised by analysts at UBS Group AG from $35.00 to $38.00. They now have a “buy” rating on the stock.
• 11/4/2025 – Syndax Pharmaceuticals had its price target raised by analysts at Barclays PLC from $19.00 to $22.00. They now have an “overweight” rating on the stock.
• 10/27/2025 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.
• 10/27/2025 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 10/16/2025 – Syndax Pharmaceuticals is now covered by analysts at HC Wainwright. They set a “buy” rating and a $40.00 price target on the stock.
• 10/15/2025 – Syndax Pharmaceuticals was upgraded by analysts at HC Wainwright to a “strong-buy” rating.
• 10/8/2025 – Syndax Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Syndax Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/19/2025 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.
• 9/10/2025 – Syndax Pharmaceuticals is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $44.00 price target on the stock.
• 9/5/2025 – Syndax Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $20.00 to $24.00. They now have a “buy” rating on the stock.

Insider Activity

In related news, CEO Michael A. Metzger sold 157,307 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the transaction, the chief executive officer directly owned 298,661 shares in the company, valued at $4,901,027.01. The trade was a 34.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Dennis Podlesak sold 19,200 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $15.84, for a total value of $304,128.00. Following the sale, the director directly owned 191,763 shares in the company, valued at $3,037,525.92. The trade was a 9.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 195,707 shares of company stock worth $3,183,904 over the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).